Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor.
Le Wang,George A. Doherty,Andrew S. Judd,Zhi-Fu Tao,T. Matthew Hansen,Robin R. Frey,Xiaohong Song,Milan Bruncko,Aaron R. Kunzer,Xilu Wang,Michael D. Wendt,John A. Flygare,Nathaniel D. Catron,Russell A. Judge,Chang H. Park,Shashank Shekhar,Darren C. Phillips,Paul Nimmer,Morey L. Smith,Stephen K. Tahir,Yu Xiao,John Xue,Haichao Zhang, Phuong N. Le,Michael J. Mitten,Erwin R. Boghaert,Wenqing Gao,Peter Kovar,Edna F. Choo,Dolores Diaz,Wayne J. Fairbrother,Steven W. Elmore,Deepak Sampath,Joel D. Leverson,Andrew James Souers ACS Medicinal Chemistry Letters（2020）
Key words
BCL-X-L,BCL-2,apoptosis,A-1331852,A-1155463,structure-based drug design (SBDD)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper